<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299063</url>
  </required_header>
  <id_info>
    <org_study_id>1000044746</org_study_id>
    <nct_id>NCT02299063</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Effect on Mitochondrial Function</brief_title>
  <official_title>The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that in addition to a known sympatholytic effect,
      intraoperative dexmedetomidine reduces adverse changes in mitochondrial function and
      structure attenuating ischaemia-reperfusion and end-organ injury for children with non
      cyanotic congenital heart defects having corrective heart surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PICO: For children with non cyanotic congenital heart defects having corrective heart surgery
      (P) does intraoperative dexmedetomidine (I) reduce real-time changes in mitochondrial
      function and content (O) compared with children not receiving dexmedetomidine (C).

      The study drug (dexmedetomidine or placebo) will be mixed in a standardized syringe of
      4mcg/mL for active syringes or 50mL 0.9% sodium chloride for placebo. Blinded syringes will
      be prepared by the Research Support Pharmacy.

      Administration is via the existing central venous line. A bolus dose of 0.125mL/kg (0.5
      mcg/kg dexmedetomidine) infused over 10 minutes will be administered, followed by a
      continuous infusion for the duration of the surgery. The dexmedetomidine/placebo continuous
      infusion (CI) dose will run at 0.15mL/kg/hr (0.6 mcg/kg/hr dexmedetomidine).

      Blood samples will be obtained from each child at three points in the operating room: 1)
      after the induction of anesthesia, 2) at the first separation from CPB (prior to
      administration of blood products), and 3) at the end of the surgery.

      Samples obtained will be analyzed for mitochondrial function and morphology, total cellular
      mitochondrial biomass, and mitochondrial deoxyribonucleic acid (mtDNA) damage:

        1. After isolating lymphocytes, we will use high content imaging (HCI) to assess
           mitochondrial function and morphology. The lymphocytes will be stained with
           tetramethylrhodamine methyl ester (TMRM), which stains mitochondria in proportion to
           mitochondrial membrane potential, giving a metric for mitochondrial function. In
           addition, the cells will be stained with MitoTracker Green®, which can be used to assess
           mitochondrial morphology. Mitochondrial morphology will be quantified in a non-biased
           fashion using a mathematical image analysis algorithm.

        2. After extraction of genomic DNA, total cellular mitochondrial biomass and mitochondrial
           DNA damage will be measured using traditional and long-patch quantitative polymerase
           chain reaction (PCR).

      Myocardial tissue will be also collected prior to closure of the atriotomy. Samples will be
      placed into 3% buffered glutaraldehyde at the time of biopsy, and imaging of mitochondrial
      structure using electron microscopy will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial function (use high content imaging (HCI)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The primary outcomes for mitochondria will be grouped into mitochondrial function, morphology, content and mtDNA damage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine level (Marker of acute renal injury)</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Marker of acute renal injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function (Left ventricular ejection fraction measured by trans-thoracic echocardiography)</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Left ventricular ejection fraction measured by trans-thoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropes and vasopressors (Duration and dose of inotropes and vasopressors after surgery)</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Duration and dose of inotropes and vasopressors after surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analgesic effects (Morphine equivalent dose of narcotics consumed)</measure>
    <time_frame>Perioperative (from induction of anesthesia for 24 hours)</time_frame>
    <description>Morphine equivalent dose of narcotics consumed</description>
  </other_outcome>
  <other_outcome>
    <measure>Sedative effects (Duration of intubation)</measure>
    <time_frame>Perioperative (from induction of anesthesia for 24 hours)</time_frame>
    <description>Duration of intubation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Complication of Anesthesia</condition>
  <condition>Ischaemia-reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Placebo (0.9% Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <arm_group_label>Placebo (0.9% Saline)</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 3 - 36 months

          -  having primary corrective heart surgery

        Exclusion Criteria:

          -  recent surgery (&lt; 3 months)

          -  previous chemotherapy

          -  previous transfusion of blood products

          -  neurodevelopmental disorders (including Trisomy 21)

          -  supplemental oxygen requirement (&lt; 3 months)

          -  asthma requiring regular therapy

          -  obstructive sleep apnea

          -  the presence of concurrent infection or inflammation

          -  a known allergy to dexmedetomidine hydrochloride
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D O'Leary, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James D O'Leary, MBBCh</last_name>
    <phone>(416) 813-1500</phone>
    <phone_ext>228845</phone_ext>
    <email>james.oleary@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James D O'Leary, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Coles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason T Maynes, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Stocki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>James O'Leary</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Mitochondria</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Heart Defects, Congenital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

